董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian S. Tyler | 男 | Chief Executive Officer and Director | 58 | 2016.17万美元 | 7.08 | 2025-07-30 |
| Julie L. Gerberding | 女 | Director | 69 | 12.38万美元 | 未持股 | 2025-07-30 |
| Dominic J. Caruso | 男 | Director | 67 | 35.87万美元 | 0.03 | 2025-07-30 |
| Kathleen Wilson Thompson | 女 | Director | 68 | 33.87万美元 | 未持股 | 2025-07-30 |
| Lynne M. Doughtie | 女 | Director | 62 | 12.38万美元 | 未持股 | 2025-07-30 |
| James H. Hinton | 男 | Director | 66 | 33.37万美元 | 未持股 | 2025-07-30 |
| Kevin Ozan | 男 | Director | 62 | 34.87万美元 | 0.0015 | 2025-07-30 |
| Deborah Dunsire | 女 | Director | 62 | 34.60万美元 | 0.0028 | 2025-07-30 |
| Donald R. Knauss | 男 | Director | 74 | 59.40万美元 | 0.21 | 2025-07-30 |
| W. Roy Dunbar | 男 | Director | 64 | 33.37万美元 | 未持股 | 2025-07-30 |
| Maria Martinez | 女 | Director | 67 | 35.37万美元 | 0.03 | 2025-07-30 |
| Bradley E. Lerman | 男 | Director | 68 | 35.37万美元 | 未持股 | 2025-07-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian S. Tyler | 男 | Chief Executive Officer and Director | 58 | 2016.17万美元 | 7.08 | 2025-07-30 |
| Britt J. Vitalone | -- | Executive Vice President and Chief Financial Officer | 56 | 768.22万美元 | 1.46 | 2025-07-30 |
| LeAnn B. Smith | -- | Executive Vice President and Chief Human Resources Officer | 50 | 371.79万美元 | 0.28 | 2025-07-30 |
| Michele Lau | 女 | Executive Vice President and Chief Legal Officer | 49 | 522.67万美元 | 0.34 | 2025-07-30 |
| Napoleon B. Rutledge Jr. | -- | Senior Vice President and Controller | -- | 未披露 | 未持股 | 2025-07-30 |
| Thomas L. Rodgers | -- | Executive Vice President, Chief Strategy and Business Development Officer | 54 | 未披露 | 未持股 | 2025-07-30 |
董事简历
中英对照 | 中文 | 英文- Brian S. Tyler
-
Brian S. Tyler，于1997年开始任职，2006年4月至2010年12月，担任麦克森公司医疗手术部总裁。2011年1月至2012年8月，担任麦克森美国药业公司的总裁。自2012年8月起，担任麦克森公司战略和业务发展部的执行副总裁。公司战略和业务发展从2012年到2015年；执行副总裁（从2015年到2016年）；北美制药分销和服务的总裁（从2015年到2016年）；总裁兼首席运营官（从2016年到2017年）；AG的管理委员会主席（从2017年到2018年）；2018年8月至2019年3月担任公司总裁和首席运营官；自2019年4月1日起担任McKesson Corporation的首席执行官。
Brian S. Tyler,has served as chief executive officer of McKesson Corporation since April 2019 and previously served as the Company's president and chief operating officer from August 2018 to March 2019.Mr. Tyler served as chairman of the Management Board of McKesson Europe AG from 2017 to 2018, president and chief operating officer of McKesson Europe from 2016 to 2017, president of McKesson's North American Pharmaceutical Distribution and Services from 2015 to 2016, and McKesson's executive vice president, corporate strategy and business development from 2012 to 2015.Mr. Tyler previously served in various other leadership roles at McKesson, including as president of U.S. Pharmaceutical, president of McKesson Medical-Surgical, and president of McKesson Specialty Health.Mr. Tyler is a member of the board of directors of the International Federation of Pharmaceutical Wholesalers (IFPW) and a member of the IFPW Foundation board of directors.He is a member of the American Cancer Society's CEOs Against Cancer group in the North Texas chapter.Mr. Tyler earned his Ph.D. from the University of Chicago, Department of Economics specializing in industrial organization, labor economics and public finance / project evaluation. - Brian S. Tyler，于1997年开始任职，2006年4月至2010年12月，担任麦克森公司医疗手术部总裁。2011年1月至2012年8月，担任麦克森美国药业公司的总裁。自2012年8月起，担任麦克森公司战略和业务发展部的执行副总裁。公司战略和业务发展从2012年到2015年；执行副总裁（从2015年到2016年）；北美制药分销和服务的总裁（从2015年到2016年）；总裁兼首席运营官（从2016年到2017年）；AG的管理委员会主席（从2017年到2018年）；2018年8月至2019年3月担任公司总裁和首席运营官；自2019年4月1日起担任McKesson Corporation的首席执行官。
- Brian S. Tyler,has served as chief executive officer of McKesson Corporation since April 2019 and previously served as the Company's president and chief operating officer from August 2018 to March 2019.Mr. Tyler served as chairman of the Management Board of McKesson Europe AG from 2017 to 2018, president and chief operating officer of McKesson Europe from 2016 to 2017, president of McKesson's North American Pharmaceutical Distribution and Services from 2015 to 2016, and McKesson's executive vice president, corporate strategy and business development from 2012 to 2015.Mr. Tyler previously served in various other leadership roles at McKesson, including as president of U.S. Pharmaceutical, president of McKesson Medical-Surgical, and president of McKesson Specialty Health.Mr. Tyler is a member of the board of directors of the International Federation of Pharmaceutical Wholesalers (IFPW) and a member of the IFPW Foundation board of directors.He is a member of the American Cancer Society's CEOs Against Cancer group in the North Texas chapter.Mr. Tyler earned his Ph.D. from the University of Chicago, Department of Economics specializing in industrial organization, labor economics and public finance / project evaluation.
- Julie L. Gerberding
-
Julie L. Gerberding于2017年3月3日被任命为塞纳公司董事会成员。她被任命为Merck＆Co.，Inc执行副总裁兼首席耐心官，战略传播，全球公共政策和人口健康。默克“。默克是一家全球性的医疗保健公司，通过其处方药，疫苗，生物疗法和动物保健产品（通过其合资企业直接销售）提供创新的健康解决方案。在此职位上，Gerberding博士负责默克的全球公共政策，企业责任和沟通职能，以及默克基金会和默克母亲项目。 Gerberding博士于2010年1月加入默克，出任默克疫苗总裁，并于2015年12月晋升为战略通信，全球公共政策和人口健康执行副总裁。在加入默克之前，Gerberding博士曾担任美国疾病控制和预防（CDC）从2002 - 2009年，在此之前，担任医疗保健质量促进司司长。在加入疾病预防控制中心之前，Gerberding博士曾是加利福尼亚大学旧金山分校（UCSF）传染病学系的终身教职人员。她继续担任加州大学旧金山分校临床副教授。
Julie L. Gerberding has been a member of the Board of Directors of the Company since March 2017. She has been the Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck & Co., Inc. "Merck" (NYSE: MRK) since July 2016 and will continue to hold that position until she becomes the Chief Executive Officer of The Foundation for the National Institutes of Health on May 16 2022. Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. In this position, Dr. Gerberding is responsible for Merck's global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Dr. Gerberding also leads new partnership initiatives that accelerate Merck's ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations.Dr. Gerberding joined Merck as President of Merck Vaccines in January 2010 and was promoted to Executive Vice President for Strategic Communications, Global Public Policy and Population Health in December 2015. Prior to joining Merck, Dr. Gerberding served as Director of the U.S. Centers for Disease Control and Prevention ("CDC") from 2002-2009 and before that served as Director of the Division of Healthcare Quality Promotion. Before joining the CDC, Dr. Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco ("UCSF"). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. Dr. Gerberding is a member of the board of directors of The Foundation for the National Institutes of Health and AfterNext HealthTech Acquisition Corp. ( NYSE: AFTR). - Julie L. Gerberding于2017年3月3日被任命为塞纳公司董事会成员。她被任命为Merck＆Co.，Inc执行副总裁兼首席耐心官，战略传播，全球公共政策和人口健康。默克“。默克是一家全球性的医疗保健公司，通过其处方药，疫苗，生物疗法和动物保健产品（通过其合资企业直接销售）提供创新的健康解决方案。在此职位上，Gerberding博士负责默克的全球公共政策，企业责任和沟通职能，以及默克基金会和默克母亲项目。 Gerberding博士于2010年1月加入默克，出任默克疫苗总裁，并于2015年12月晋升为战略通信，全球公共政策和人口健康执行副总裁。在加入默克之前，Gerberding博士曾担任美国疾病控制和预防（CDC）从2002 - 2009年，在此之前，担任医疗保健质量促进司司长。在加入疾病预防控制中心之前，Gerberding博士曾是加利福尼亚大学旧金山分校（UCSF）传染病学系的终身教职人员。她继续担任加州大学旧金山分校临床副教授。
- Julie L. Gerberding has been a member of the Board of Directors of the Company since March 2017. She has been the Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck & Co., Inc. "Merck" (NYSE: MRK) since July 2016 and will continue to hold that position until she becomes the Chief Executive Officer of The Foundation for the National Institutes of Health on May 16 2022. Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. In this position, Dr. Gerberding is responsible for Merck's global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Dr. Gerberding also leads new partnership initiatives that accelerate Merck's ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations.Dr. Gerberding joined Merck as President of Merck Vaccines in January 2010 and was promoted to Executive Vice President for Strategic Communications, Global Public Policy and Population Health in December 2015. Prior to joining Merck, Dr. Gerberding served as Director of the U.S. Centers for Disease Control and Prevention ("CDC") from 2002-2009 and before that served as Director of the Division of Healthcare Quality Promotion. Before joining the CDC, Dr. Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco ("UCSF"). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. Dr. Gerberding is a member of the board of directors of The Foundation for the National Institutes of Health and AfterNext HealthTech Acquisition Corp. ( NYSE: AFTR).
- Dominic J. Caruso
-
Dominic J. Caruso于2018年8月从强生公司（Johnson＆Johnson）退任执行副总裁兼首席财务官，强生公司自2007年起担任该职位。强生公司自2007年起担任该职位。他领导该公司的财务和投资者关系活动以及采购组织。 Centocor与强生公司合并完成后，Caruso先生于1999年10月加入强生公司，担任Centocor，Inc.的首席财务官。在加入Centocor之前，他在毕马威会计师事务所拥有丰富的行业经验。 Caruso先生积极参与全球的政府关系活动，包括曾担任美国商会“健康与经济全球倡议”的联合主席。他目前是费城儿童医院和囊性纤维化基金会的董事会成员。
Dominic J. Caruso,retired as executive vice president and chief financial officer of Johnson & Johnson, a manufacturer of medical devices and pharmaceutical products, in August 2018, having served in the role since 2007.He led the company's financial and investor relations activities, as well as the procurement organization.Mr. Caruso joined Johnson & Johnson in October 1999 as chief financial officer for Centocor, Inc., upon the completion of the merger of Centocor and Johnson & Johnson.Prior to joining Centocor, he had varied industry experiences with KPMG.Mr. Caruso was actively involved in government relations activities globally, including having served as co-chair of the U.S. Chamber of Commerce Global Initiative on Health and the Economy. - Dominic J. Caruso于2018年8月从强生公司（Johnson＆Johnson）退任执行副总裁兼首席财务官，强生公司自2007年起担任该职位。强生公司自2007年起担任该职位。他领导该公司的财务和投资者关系活动以及采购组织。 Centocor与强生公司合并完成后，Caruso先生于1999年10月加入强生公司，担任Centocor，Inc.的首席财务官。在加入Centocor之前，他在毕马威会计师事务所拥有丰富的行业经验。 Caruso先生积极参与全球的政府关系活动，包括曾担任美国商会“健康与经济全球倡议”的联合主席。他目前是费城儿童医院和囊性纤维化基金会的董事会成员。
- Dominic J. Caruso,retired as executive vice president and chief financial officer of Johnson & Johnson, a manufacturer of medical devices and pharmaceutical products, in August 2018, having served in the role since 2007.He led the company's financial and investor relations activities, as well as the procurement organization.Mr. Caruso joined Johnson & Johnson in October 1999 as chief financial officer for Centocor, Inc., upon the completion of the merger of Centocor and Johnson & Johnson.Prior to joining Centocor, he had varied industry experiences with KPMG.Mr. Caruso was actively involved in government relations activities globally, including having served as co-chair of the U.S. Chamber of Commerce Global Initiative on Health and the Economy.
- Kathleen Wilson Thompson
-
Kathleen Wilson Thompson自2018年12月起担任董事会成员。Wilson Thompson女士自2014年12月起担任全球制药和福利公司Walgreens Boots Alliance，Inc.的执行副总裁兼全球首席人力资源官，并曾于2010年1月至2014年12月期间担任高级副总裁兼首席人力资源官。在加入Walgreens之前，Wilson Thompson女士于2005年7月至2009年12月在Kellogg Company（一家食品制造公司）担任各种法律和运营职务，最近一次担任其全球人力资源高级副总裁。Wilson Thompson女士还担任Ashland Global Holdings Inc.的董事会成员，并在2009年至2018年期间担任Vulcan Materials Company的董事会成员。Wilson Thompson女士拥有密歇根大学的英国文学学士学位和韦恩州立大学的法学博士和法学硕士学位。她从1992年到2009年担任过凯洛格数个职位，离开时任该公司全球人力资源高级副总裁。1986年到1991年，她还在为密歇根州法明顿山国家公司担任副总裁以及员工诉讼和银行法律顾问。她于1979年在安阿伯市密歇根大学获得文学学士学位，于1982年在底特律的韦恩州立大学获得法学博士学位，于1996年在韦恩州立大学获得企业和金融法律硕士。她是NAACP特别贡献基金董事会的受托人。她也被黑带企业评为“美国企业界高管100强”。
Kathleen Wilson Thompson served as Executive Vice President and Global Chief Human Resces Officer of Walgreens Boots Alliance, Inc. ("Walgreens"), a global pharmacy and llbeing company, from December 2014 until her retirement in January 2021, and previoly served as Senior Vice President and Chief Human Resces Officer from January 2010 to December 2014 at Walgreens. Prior to Walgreens, Ms. Wilson Thompson held vario legal and operational roles at The Kellogg Company, a food manufacturing company, from January 1991 to December 2009, including most recently as its Senior Vice President, Global Human Resces. Ms. Wilson Thompson has served on the board of directors of Wolverine World Wide, Inc. since May 2021 and McKesson Corporation since January 2022. She has also served on the board of directors of Health Care Service Corporation since October 2024. Ms. Wilson Thompson previoly served on the board of directors of Ashland Global Holdings Inc. from 2017 to 2020. Ms. Wilson Thompson holds an A.B. in English Literature from the University of Michigan and a J.D. and LL.M. (Corporate and Finance Law) from Wayne State University. - Kathleen Wilson Thompson自2018年12月起担任董事会成员。Wilson Thompson女士自2014年12月起担任全球制药和福利公司Walgreens Boots Alliance，Inc.的执行副总裁兼全球首席人力资源官，并曾于2010年1月至2014年12月期间担任高级副总裁兼首席人力资源官。在加入Walgreens之前，Wilson Thompson女士于2005年7月至2009年12月在Kellogg Company（一家食品制造公司）担任各种法律和运营职务，最近一次担任其全球人力资源高级副总裁。Wilson Thompson女士还担任Ashland Global Holdings Inc.的董事会成员，并在2009年至2018年期间担任Vulcan Materials Company的董事会成员。Wilson Thompson女士拥有密歇根大学的英国文学学士学位和韦恩州立大学的法学博士和法学硕士学位。她从1992年到2009年担任过凯洛格数个职位，离开时任该公司全球人力资源高级副总裁。1986年到1991年，她还在为密歇根州法明顿山国家公司担任副总裁以及员工诉讼和银行法律顾问。她于1979年在安阿伯市密歇根大学获得文学学士学位，于1982年在底特律的韦恩州立大学获得法学博士学位，于1996年在韦恩州立大学获得企业和金融法律硕士。她是NAACP特别贡献基金董事会的受托人。她也被黑带企业评为“美国企业界高管100强”。
- Kathleen Wilson Thompson served as Executive Vice President and Global Chief Human Resces Officer of Walgreens Boots Alliance, Inc. ("Walgreens"), a global pharmacy and llbeing company, from December 2014 until her retirement in January 2021, and previoly served as Senior Vice President and Chief Human Resces Officer from January 2010 to December 2014 at Walgreens. Prior to Walgreens, Ms. Wilson Thompson held vario legal and operational roles at The Kellogg Company, a food manufacturing company, from January 1991 to December 2009, including most recently as its Senior Vice President, Global Human Resces. Ms. Wilson Thompson has served on the board of directors of Wolverine World Wide, Inc. since May 2021 and McKesson Corporation since January 2022. She has also served on the board of directors of Health Care Service Corporation since October 2024. Ms. Wilson Thompson previoly served on the board of directors of Ashland Global Holdings Inc. from 2017 to 2020. Ms. Wilson Thompson holds an A.B. in English Literature from the University of Michigan and a J.D. and LL.M. (Corporate and Finance Law) from Wayne State University.
- Lynne M. Doughtie
-
Lynne M. Doughtie，是最大的专业服务公司之一毕马威美国公司的前任董事长兼首席执行官。她在2015年至2020年期间担任这一职务，成为公司历史上首位同时担任董事长和首席执行官的女性。她还是毕马威全球董事会和执行委员会的成员。Doughtie在1985年加入毕马威审计业务并担任多个国家、区域和全球领导职务后，领导了毕马威在美国的咨询业务，包括担任项目合作伙伴。Doughtie于1985年获得弗吉尼亚理工学院和州立大学（Virginia Tech）/潘普林商学院会计学学士学位，并获得公共会计师认证。
Lynne M. Doughtie,is the former chair and chief executive officer of KPMG U.S., one of the largest professional services firms. She held this role from 2015 to 2020, becoming the first woman to serve as both chair and CEO in the firm's history. She also was a member of KPMG's Global Board and Executive Committee.Ms. Doughtie led KPMG's advisory business in the U.S. after joining KPMG's audit practice in 1985 and serving in a number of national, regional and global leadership roles, including as lead engagement partner.Ms. Doughtie earned a B.S. in accounting from Virginia Polytechnic Institute and State University (Virginia Tech)/Pamplin College of Business in 1985, as well as her certification as a public accountant. - Lynne M. Doughtie，是最大的专业服务公司之一毕马威美国公司的前任董事长兼首席执行官。她在2015年至2020年期间担任这一职务，成为公司历史上首位同时担任董事长和首席执行官的女性。她还是毕马威全球董事会和执行委员会的成员。Doughtie在1985年加入毕马威审计业务并担任多个国家、区域和全球领导职务后，领导了毕马威在美国的咨询业务，包括担任项目合作伙伴。Doughtie于1985年获得弗吉尼亚理工学院和州立大学（Virginia Tech）/潘普林商学院会计学学士学位，并获得公共会计师认证。
- Lynne M. Doughtie,is the former chair and chief executive officer of KPMG U.S., one of the largest professional services firms. She held this role from 2015 to 2020, becoming the first woman to serve as both chair and CEO in the firm's history. She also was a member of KPMG's Global Board and Executive Committee.Ms. Doughtie led KPMG's advisory business in the U.S. after joining KPMG's audit practice in 1985 and serving in a number of national, regional and global leadership roles, including as lead engagement partner.Ms. Doughtie earned a B.S. in accounting from Virginia Polytechnic Institute and State University (Virginia Tech)/Pamplin College of Business in 1985, as well as her certification as a public accountant.
- James H. Hinton
-
James H. Hinton 目前是私人股本公司威尔士卡森·安德森（WelshCarsonAnderson&Stowe）的运营合伙人。从2017年到2021，他担任贝勒·斯科特和怀特健康公司（Baylor Scott&White Health）的首席执行官。贝勒·斯科特和怀特健康公司是得克萨斯州最大的非营利医疗系统，也是美国最大的非营利医疗系统之一。从1983年开始，Hinton 先生担任非营利长老会医疗服务公司（Presbyterian Healthcare Services）的总裁兼首席执行官21年，Presbyterian Healthcare Services 公司是新墨西哥州最大的非营利医疗服务提供商。在此期间，他是美国医院协会董事会成员，并于2014年担任董事会主席。Hinton先生拥有亚利桑那州立大学医疗管理硕士学位和新墨西哥大学经济学学士学位。
James H. Hinton,currently serves as an operating partner for the private equity firm Welsh, Carson, Anderson & Stowe.From 2017 to 2021, he served as the CEO of Baylor Scott & White Health, the largest not-for-profit health system in Texas and one of the largest in the U.S.Mr. Hinton joined Presbyterian Healthcare Services, New Mexico's largest not-for-profit healthcare provider, in 1983 and he served as their CEO from 1995 to 2016.During that time, he was a member of the American Hospital Association Board of Trustees and served as its Chair in 2014.Mr. Hinton holds a master's degree in healthcare administration from Arizona State University and a bachelor's degree in economics from the University of New Mexico. - James H. Hinton 目前是私人股本公司威尔士卡森·安德森（WelshCarsonAnderson&Stowe）的运营合伙人。从2017年到2021，他担任贝勒·斯科特和怀特健康公司（Baylor Scott&White Health）的首席执行官。贝勒·斯科特和怀特健康公司是得克萨斯州最大的非营利医疗系统，也是美国最大的非营利医疗系统之一。从1983年开始，Hinton 先生担任非营利长老会医疗服务公司（Presbyterian Healthcare Services）的总裁兼首席执行官21年，Presbyterian Healthcare Services 公司是新墨西哥州最大的非营利医疗服务提供商。在此期间，他是美国医院协会董事会成员，并于2014年担任董事会主席。Hinton先生拥有亚利桑那州立大学医疗管理硕士学位和新墨西哥大学经济学学士学位。
- James H. Hinton,currently serves as an operating partner for the private equity firm Welsh, Carson, Anderson & Stowe.From 2017 to 2021, he served as the CEO of Baylor Scott & White Health, the largest not-for-profit health system in Texas and one of the largest in the U.S.Mr. Hinton joined Presbyterian Healthcare Services, New Mexico's largest not-for-profit healthcare provider, in 1983 and he served as their CEO from 1995 to 2016.During that time, he was a member of the American Hospital Association Board of Trustees and served as its Chair in 2014.Mr. Hinton holds a master's degree in healthcare administration from Arizona State University and a bachelor's degree in economics from the University of New Mexico.
- Kevin Ozan
-
Kevin Ozan，最近于2022年9月至2023年6月担任战略计划高级执行副总裁，并于2015年3月至2022年8月担任全球领先的食品服务零售商麦当劳公司执行副总裁兼首席财务官。Ozan从1997年到2015年在麦当劳的财务和投资者关系团队中担任过越来越多的职责。在加入麦当劳之前，他在安永的审计和并购业务部门工作了十多年。Ozan目前担任Cineworld的董事会成员，Cineworld是一家私营公司，拥有世界上最大的影院业务之一。Ozan拥有密歇根大学会计学学士学位和西北大学凯洛格管理学院硕士学位。
Kevin Ozan,most recently served as senior executive vice president, strategic initiatives from September 2022 to June 2023 and executive vice president and chief financial officer from March 2015 to August 2022 of McDonald's Corporation, a leading global food service retailer.Mr. Ozan held various roles of increasing responsibility across the financial and investor relations teams at McDonald's from 1997 to 2015.Prior to joining McDonald's, he worked for over a decade in Ernst & Young's audit and mergers and acquisitions practices.Mr. Ozan currently serves on the board of directors of Cineworld, a private company with one of the largest cinema businesses in the world.Mr. Ozan has a bachelor's degree in accounting from the University of Michigan and a master's degree in business from the Kellogg School of Management at Northwestern University. - Kevin Ozan，最近于2022年9月至2023年6月担任战略计划高级执行副总裁，并于2015年3月至2022年8月担任全球领先的食品服务零售商麦当劳公司执行副总裁兼首席财务官。Ozan从1997年到2015年在麦当劳的财务和投资者关系团队中担任过越来越多的职责。在加入麦当劳之前，他在安永的审计和并购业务部门工作了十多年。Ozan目前担任Cineworld的董事会成员，Cineworld是一家私营公司，拥有世界上最大的影院业务之一。Ozan拥有密歇根大学会计学学士学位和西北大学凯洛格管理学院硕士学位。
- Kevin Ozan,most recently served as senior executive vice president, strategic initiatives from September 2022 to June 2023 and executive vice president and chief financial officer from March 2015 to August 2022 of McDonald's Corporation, a leading global food service retailer.Mr. Ozan held various roles of increasing responsibility across the financial and investor relations teams at McDonald's from 1997 to 2015.Prior to joining McDonald's, he worked for over a decade in Ernst & Young's audit and mergers and acquisitions practices.Mr. Ozan currently serves on the board of directors of Cineworld, a private company with one of the largest cinema businesses in the world.Mr. Ozan has a bachelor's degree in accounting from the University of Michigan and a master's degree in business from the Kellogg School of Management at Northwestern University.
- Deborah Dunsire
-
Deborah Dunsire，医学博士，自2017年4月起担任董事会成员。Dunsire博士此前曾于2017年1月至2018年3月担任私人生物制药公司Xtuit Pharmaceuticals，Inc.的总裁兼首席执行官兼董事。任职XTUIT公司之前，她曾担任Forum Pharmaceuticals公司（私人制药公司）的总裁兼首席执行官兼董事（从2013年7月到2016年5月）。在加入Forum之前，Dunsire博士曾于2010年6月至2011年6月在Takeda Pharmaceutical Company Limited（一家公开上市的制药公司）担任公司高管，并于2011年6月至2013年6月担任董事。她曾担任Millennium Pharmaceuticals公司（上市生物制药公司）的总裁兼首席执行官兼董事（从2005年到2008年公司被Takeda公司收购）。然后在2008年至2013年期间担任Millenium收购后的Takeda Oncology Company的总裁兼首席执行官。加入Millenium之前，Dunsire从1988年到2005年在Novartis Pharma AG担任多个职责递增的职位。Dunsire博士曾于2006年12月至2015年4月担任Allergan, Inc.（一家公开上市的制药公司）的董事。自2018年9月1日起，Dunsire博士担任H.Lundbeck A/S。的总裁兼首席执行官。她目前担任Alexion Pharmaceuticals Inc.的董事会成员。她在University of the Witwatersrand获得MBBCH。
Deborah Dunsire,served as President and CEO of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases, from 2018 to 2023.From 2017 to 2018, she served as President and CEO of XTuit Pharmaceuticals, a biopharmaceutical company focused on cancer treatments.Prior to her employment with XTuit Pharmaceuticals, Dr. Dunsire held various executive leadership roles at FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals.Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa and received her medical degree from the University of Witwatersrand in Johannesburg, South Africa. - Deborah Dunsire，医学博士，自2017年4月起担任董事会成员。Dunsire博士此前曾于2017年1月至2018年3月担任私人生物制药公司Xtuit Pharmaceuticals，Inc.的总裁兼首席执行官兼董事。任职XTUIT公司之前，她曾担任Forum Pharmaceuticals公司（私人制药公司）的总裁兼首席执行官兼董事（从2013年7月到2016年5月）。在加入Forum之前，Dunsire博士曾于2010年6月至2011年6月在Takeda Pharmaceutical Company Limited（一家公开上市的制药公司）担任公司高管，并于2011年6月至2013年6月担任董事。她曾担任Millennium Pharmaceuticals公司（上市生物制药公司）的总裁兼首席执行官兼董事（从2005年到2008年公司被Takeda公司收购）。然后在2008年至2013年期间担任Millenium收购后的Takeda Oncology Company的总裁兼首席执行官。加入Millenium之前，Dunsire从1988年到2005年在Novartis Pharma AG担任多个职责递增的职位。Dunsire博士曾于2006年12月至2015年4月担任Allergan, Inc.（一家公开上市的制药公司）的董事。自2018年9月1日起，Dunsire博士担任H.Lundbeck A/S。的总裁兼首席执行官。她目前担任Alexion Pharmaceuticals Inc.的董事会成员。她在University of the Witwatersrand获得MBBCH。
- Deborah Dunsire,served as President and CEO of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases, from 2018 to 2023.From 2017 to 2018, she served as President and CEO of XTuit Pharmaceuticals, a biopharmaceutical company focused on cancer treatments.Prior to her employment with XTuit Pharmaceuticals, Dr. Dunsire held various executive leadership roles at FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals.Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa and received her medical degree from the University of Witwatersrand in Johannesburg, South Africa.
- Donald R. Knauss
-
Donald R. Knauss，2006年10月成为公司董事长及首席执行官。他2004年2月至2006年9月任可口可乐公司执行副总裁，可口可乐公司北美总裁及首席运营官。此前，他是可口可乐北美公司零售部门主任，Minute Maid公司（可口可乐公司分部）总裁及首席执行官。在加入可口可乐公司之前，他在百事科勒公司和保洁公司担任多项市场营销职位，也曾担任美国海军陆战队军官。
Donald R. Knauss,retired from The Clorox Company, a multinational manufacturer and marketer of consumer and professional products, in 2015, having served as executive chairman of the board from November 2014 until July 2015 and chairman and chief executive officer from October 2006 until November 2014.He was executive vice president of The Coca-Cola Company and president and chief operating officer for Coca-Cola North America from February 2004 until September 2006.Prior to his employment with The Coca-Cola Company, he held various positions in marketing and sales with PepsiCo, Inc. and Procter & Gamble, and he also served as an officer in the United States Marine Corps.Mr. Knauss also serves on the board of trustees for the University of San Diego. - Donald R. Knauss，2006年10月成为公司董事长及首席执行官。他2004年2月至2006年9月任可口可乐公司执行副总裁，可口可乐公司北美总裁及首席运营官。此前，他是可口可乐北美公司零售部门主任，Minute Maid公司（可口可乐公司分部）总裁及首席执行官。在加入可口可乐公司之前，他在百事科勒公司和保洁公司担任多项市场营销职位，也曾担任美国海军陆战队军官。
- Donald R. Knauss,retired from The Clorox Company, a multinational manufacturer and marketer of consumer and professional products, in 2015, having served as executive chairman of the board from November 2014 until July 2015 and chairman and chief executive officer from October 2006 until November 2014.He was executive vice president of The Coca-Cola Company and president and chief operating officer for Coca-Cola North America from February 2004 until September 2006.Prior to his employment with The Coca-Cola Company, he held various positions in marketing and sales with PepsiCo, Inc. and Procter & Gamble, and he also served as an officer in the United States Marine Corps.Mr. Knauss also serves on the board of trustees for the University of San Diego.
- W. Roy Dunbar
-
W. Roy Dunbar，曾担任技术公司和Web服务提供商Network Solutions的董事会主席，并于2008年1月至2009年10月担任首席执行官。Dunbar先生于2004年9月至2008年1月期间担任万事达卡公司的Global Technology和运营总裁。在加入万事达之前，Dunbar先生曾在礼来公司工作了14年，担任洲际业务总裁，更早时担任首席信息官。他目前担任美国最大的能源控股公司之一杜克能源公司、全国药品批发分销商McKesson Corporation和全国景观用品批发分销商SiteOne Landscape Supply，Inc.的董事。Dunbar先生此前曾担任哈门那，Inc.、利盟国际和iGate的董事。
W. Roy Dunbar,has served as one of directors since March 2017. He was Chairman of the Board of Network Solutions, a technology company and web service provider, and was the Chief Executive Officer from January 2008 until October 2009. Mr. Dunbar also served as the President of Global Technology and Operations for MasterCard Incorporated from September 2004 until January 2008. Prior to MasterCard, Mr. Dunbar worked at Eli Lilly and Company for 14 years, serving as President of Intercontinental Operations, and earlier as Chief Information Officer. He currently serves on the Board of Directors of McKesson Corporation, Johnson Controls International PLC and Duke Energy Corporation and previously served on the boards of Humana Inc., Lexmark International and iGate. Mr. Dunbar was named to NACD Directorship 100 in 2015 and is a NACD Board Leadership Fellow. He is a graduate of Manchester University in the United Kingdom and holds an M.B.A. from Manchester Business School. - W. Roy Dunbar，曾担任技术公司和Web服务提供商Network Solutions的董事会主席，并于2008年1月至2009年10月担任首席执行官。Dunbar先生于2004年9月至2008年1月期间担任万事达卡公司的Global Technology和运营总裁。在加入万事达之前，Dunbar先生曾在礼来公司工作了14年，担任洲际业务总裁，更早时担任首席信息官。他目前担任美国最大的能源控股公司之一杜克能源公司、全国药品批发分销商McKesson Corporation和全国景观用品批发分销商SiteOne Landscape Supply，Inc.的董事。Dunbar先生此前曾担任哈门那，Inc.、利盟国际和iGate的董事。
- W. Roy Dunbar,has served as one of directors since March 2017. He was Chairman of the Board of Network Solutions, a technology company and web service provider, and was the Chief Executive Officer from January 2008 until October 2009. Mr. Dunbar also served as the President of Global Technology and Operations for MasterCard Incorporated from September 2004 until January 2008. Prior to MasterCard, Mr. Dunbar worked at Eli Lilly and Company for 14 years, serving as President of Intercontinental Operations, and earlier as Chief Information Officer. He currently serves on the Board of Directors of McKesson Corporation, Johnson Controls International PLC and Duke Energy Corporation and previously served on the boards of Humana Inc., Lexmark International and iGate. Mr. Dunbar was named to NACD Directorship 100 in 2015 and is a NACD Board Leadership Fellow. He is a graduate of Manchester University in the United Kingdom and holds an M.B.A. from Manchester Business School.
- Maria Martinez
-
Maria Martinez，在思科、赛富时和微软的工作经验使她能够对美国银行公司董事会拥有广泛的技术知识。她的领导角色为她提供了战略规划、风险管理和执行领导经验。她在上市公司董事会的经历让她洞悉了大型、复杂和受监管公司的治理。
Maria Martinez,most recently served as executive vice president and chief operating officer from March 2021 to May 2024 and was executive vice president and chief customer experience officer from April 2018 until March 2021 at Cisco Systems, Inc., a multinational digital communications technology company.Prior to joining Cisco, Ms. Martinez served in a variety of senior executive roles at Salesforce, Inc., including president, Global Customer Success and Latin America from March 2016 to April 2018; president, Sales and Customer Success from February 2013 to March 2016; executive vice president and chief growth officer from February 2012 to February 2013; and executive vice president, Customers for Life from February 2010 to February 2012.Prior to joining Salesforce, she managed the global services business for Microsoft Corporation, including professional services and customer support for all products.Ms. Martinez also has held a number of other leadership positions at Motorola, Inc. and AT&T Inc., and served as chief executive officer of Embrace Networks, Inc.Ms. Martinez holds a bachelor's degree in electrical engineering from the University of Puerto Rico and a master's degree in computer engineering from Ohio State University. - Maria Martinez，在思科、赛富时和微软的工作经验使她能够对美国银行公司董事会拥有广泛的技术知识。她的领导角色为她提供了战略规划、风险管理和执行领导经验。她在上市公司董事会的经历让她洞悉了大型、复杂和受监管公司的治理。
- Maria Martinez,most recently served as executive vice president and chief operating officer from March 2021 to May 2024 and was executive vice president and chief customer experience officer from April 2018 until March 2021 at Cisco Systems, Inc., a multinational digital communications technology company.Prior to joining Cisco, Ms. Martinez served in a variety of senior executive roles at Salesforce, Inc., including president, Global Customer Success and Latin America from March 2016 to April 2018; president, Sales and Customer Success from February 2013 to March 2016; executive vice president and chief growth officer from February 2012 to February 2013; and executive vice president, Customers for Life from February 2010 to February 2012.Prior to joining Salesforce, she managed the global services business for Microsoft Corporation, including professional services and customer support for all products.Ms. Martinez also has held a number of other leadership positions at Motorola, Inc. and AT&T Inc., and served as chief executive officer of Embrace Networks, Inc.Ms. Martinez holds a bachelor's degree in electrical engineering from the University of Puerto Rico and a master's degree in computer engineering from Ohio State University.
- Bradley E. Lerman
-
Bradley E. Lerman，担任公司的高级副总裁、总法律顾问和公司秘书（2015年1月以来），以及Medtronic, Inc.的高级副总裁、总法律顾问和公司秘书（2014年5月以来）。此前，他曾担任Federal National Mortgage Association Fannie Mae的执行副总裁、总法律顾问和公司秘书（从2012年10月到2014年5月）、Pfizer, Inc.的高级副总裁兼首席诉讼律师（从2009年1月到2012年9月）、Winston & Strawn的合伙人（从1998年8月到2009年1月）、Kirkland & Ellis的合伙人（1996年3月至1998年7月）、副独立检察官（从1994年10月到1996年3月）、伊利诺斯州的北部地区的美国助理检察官（1986年2月到1994年9月）。
Bradley E. Lerman,currently serves as the executive vice president and chief legal officer of Starbucks Corporation, a company with a multinational chain of coffeehouses and roastery reserves.Previously, Mr. Lerman served as the senior vice president, general counsel and corporate secretary of Medtronic plc, a medical device company, from 2014 to January 2022.At Medtronic, he led the company's global legal, government affairs and ethics and compliance functions. Prior to Medtronic, Mr. Lerman served as executive vice president, general counsel and corporate secretary for the Federal National Mortgage Association (Fannie Mae).Previous to Fannie Mae, he served as senior vice president, associate general counsel and chief litigation counsel for Pfizer.Mr. Lerman also served as a litigation partner at Winston & Strawn LLP in Chicago and as an assistant U.S. attorney in the Northern District of Illinois.He received a law degree from Harvard Law School and his bachelor's degree in economics from Yale University. - Bradley E. Lerman，担任公司的高级副总裁、总法律顾问和公司秘书（2015年1月以来），以及Medtronic, Inc.的高级副总裁、总法律顾问和公司秘书（2014年5月以来）。此前，他曾担任Federal National Mortgage Association Fannie Mae的执行副总裁、总法律顾问和公司秘书（从2012年10月到2014年5月）、Pfizer, Inc.的高级副总裁兼首席诉讼律师（从2009年1月到2012年9月）、Winston & Strawn的合伙人（从1998年8月到2009年1月）、Kirkland & Ellis的合伙人（1996年3月至1998年7月）、副独立检察官（从1994年10月到1996年3月）、伊利诺斯州的北部地区的美国助理检察官（1986年2月到1994年9月）。
- Bradley E. Lerman,currently serves as the executive vice president and chief legal officer of Starbucks Corporation, a company with a multinational chain of coffeehouses and roastery reserves.Previously, Mr. Lerman served as the senior vice president, general counsel and corporate secretary of Medtronic plc, a medical device company, from 2014 to January 2022.At Medtronic, he led the company's global legal, government affairs and ethics and compliance functions. Prior to Medtronic, Mr. Lerman served as executive vice president, general counsel and corporate secretary for the Federal National Mortgage Association (Fannie Mae).Previous to Fannie Mae, he served as senior vice president, associate general counsel and chief litigation counsel for Pfizer.Mr. Lerman also served as a litigation partner at Winston & Strawn LLP in Chicago and as an assistant U.S. attorney in the Northern District of Illinois.He received a law degree from Harvard Law School and his bachelor's degree in economics from Yale University.
高管简历
中英对照 | 中文 | 英文- Brian S. Tyler
Brian S. Tyler，于1997年开始任职，2006年4月至2010年12月，担任麦克森公司医疗手术部总裁。2011年1月至2012年8月，担任麦克森美国药业公司的总裁。自2012年8月起，担任麦克森公司战略和业务发展部的执行副总裁。公司战略和业务发展从2012年到2015年；执行副总裁（从2015年到2016年）；北美制药分销和服务的总裁（从2015年到2016年）；总裁兼首席运营官（从2016年到2017年）；AG的管理委员会主席（从2017年到2018年）；2018年8月至2019年3月担任公司总裁和首席运营官；自2019年4月1日起担任McKesson Corporation的首席执行官。
Brian S. Tyler,has served as chief executive officer of McKesson Corporation since April 2019 and previously served as the Company's president and chief operating officer from August 2018 to March 2019.Mr. Tyler served as chairman of the Management Board of McKesson Europe AG from 2017 to 2018, president and chief operating officer of McKesson Europe from 2016 to 2017, president of McKesson's North American Pharmaceutical Distribution and Services from 2015 to 2016, and McKesson's executive vice president, corporate strategy and business development from 2012 to 2015.Mr. Tyler previously served in various other leadership roles at McKesson, including as president of U.S. Pharmaceutical, president of McKesson Medical-Surgical, and president of McKesson Specialty Health.Mr. Tyler is a member of the board of directors of the International Federation of Pharmaceutical Wholesalers (IFPW) and a member of the IFPW Foundation board of directors.He is a member of the American Cancer Society's CEOs Against Cancer group in the North Texas chapter.Mr. Tyler earned his Ph.D. from the University of Chicago, Department of Economics specializing in industrial organization, labor economics and public finance / project evaluation.- Brian S. Tyler，于1997年开始任职，2006年4月至2010年12月，担任麦克森公司医疗手术部总裁。2011年1月至2012年8月，担任麦克森美国药业公司的总裁。自2012年8月起，担任麦克森公司战略和业务发展部的执行副总裁。公司战略和业务发展从2012年到2015年；执行副总裁（从2015年到2016年）；北美制药分销和服务的总裁（从2015年到2016年）；总裁兼首席运营官（从2016年到2017年）；AG的管理委员会主席（从2017年到2018年）；2018年8月至2019年3月担任公司总裁和首席运营官；自2019年4月1日起担任McKesson Corporation的首席执行官。
- Brian S. Tyler,has served as chief executive officer of McKesson Corporation since April 2019 and previously served as the Company's president and chief operating officer from August 2018 to March 2019.Mr. Tyler served as chairman of the Management Board of McKesson Europe AG from 2017 to 2018, president and chief operating officer of McKesson Europe from 2016 to 2017, president of McKesson's North American Pharmaceutical Distribution and Services from 2015 to 2016, and McKesson's executive vice president, corporate strategy and business development from 2012 to 2015.Mr. Tyler previously served in various other leadership roles at McKesson, including as president of U.S. Pharmaceutical, president of McKesson Medical-Surgical, and president of McKesson Specialty Health.Mr. Tyler is a member of the board of directors of the International Federation of Pharmaceutical Wholesalers (IFPW) and a member of the IFPW Foundation board of directors.He is a member of the American Cancer Society's CEOs Against Cancer group in the North Texas chapter.Mr. Tyler earned his Ph.D. from the University of Chicago, Department of Economics specializing in industrial organization, labor economics and public finance / project evaluation.
- Britt J. Vitalone
Britt J. Vitalone自2018年1月起担任执行副总裁兼首席财务官； 2014年7月至2017年12月为美国制药高级副总裁兼首席财务官； 2017年10月至2017年12月为美国制药和特殊健康部门高级副总裁兼首席财务官； 2012年3月至2014年6月，担任公司财务和并购财务高级副总裁。为公司服务14年。
Britt J. Vitalone,Executive Vice President and Chief Financial Officer since January 2018; Senior Vice President and Chief Financial Officer, U.S. Pharmaceutical from July 2014 to December 2017; Senior Vice President and Chief Financial Officer, U.S. Pharmaceutical and Specialty Health from October 2017 to December 2017; Senior Vice President of Corporate Finance and M&A Finance from March 2012 to June 2014.- Britt J. Vitalone自2018年1月起担任执行副总裁兼首席财务官； 2014年7月至2017年12月为美国制药高级副总裁兼首席财务官； 2017年10月至2017年12月为美国制药和特殊健康部门高级副总裁兼首席财务官； 2012年3月至2014年6月，担任公司财务和并购财务高级副总裁。为公司服务14年。
- Britt J. Vitalone,Executive Vice President and Chief Financial Officer since January 2018; Senior Vice President and Chief Financial Officer, U.S. Pharmaceutical from July 2014 to December 2017; Senior Vice President and Chief Financial Officer, U.S. Pharmaceutical and Specialty Health from October 2017 to December 2017; Senior Vice President of Corporate Finance and M&A Finance from March 2012 to June 2014.
- LeAnn B. Smith
LeAnn B. Smith，自2022年12月起担任执行副总裁兼首席人力资源官。此前，从2021年到2022年担任人才管理和发展高级副总裁。从2018年到2021年，担任Walmart Inc.全球企业职能部门的首席人力资源主管。在McKESSON CORPORATION服务- 2年。
LeAnn B. Smith,Executive Vice President and Chief Human Resources Officer since December 2022. Previously, Senior Vice President, Talent Management and Development from 2021 to 2022. Chief People Leader, Global Corporate Functions for Walmart Inc. (retail) from 2018 to 2021.- LeAnn B. Smith，自2022年12月起担任执行副总裁兼首席人力资源官。此前，从2021年到2022年担任人才管理和发展高级副总裁。从2018年到2021年，担任Walmart Inc.全球企业职能部门的首席人力资源主管。在McKESSON CORPORATION服务- 2年。
- LeAnn B. Smith,Executive Vice President and Chief Human Resources Officer since December 2022. Previously, Senior Vice President, Talent Management and Development from 2021 to 2022. Chief People Leader, Global Corporate Functions for Walmart Inc. (retail) from 2018 to 2021.
- Michele Lau
Michele Lau，曾担任GoDaddy的首席法务官和公司秘书。在此之前，Michele在McKesson的总法律顾问组织工作了13年，最近担任高级副总裁、公司秘书和助理总法律顾问。
Michele Lau,Executive Vice President and Chief Legal Officer since January 2024. Chief Legal Officer and Corporate Secretary, GoDaddy (technology services) from July 2021 to November 2023. Senior Vice President, Corporate Secretary and Associate General Counsel at McKesson from March 2018 to June 2021 and various other legal roles at McKesson from 2008 to 2018.- Michele Lau，曾担任GoDaddy的首席法务官和公司秘书。在此之前，Michele在McKesson的总法律顾问组织工作了13年，最近担任高级副总裁、公司秘书和助理总法律顾问。
- Michele Lau,Executive Vice President and Chief Legal Officer since January 2024. Chief Legal Officer and Corporate Secretary, GoDaddy (technology services) from July 2021 to November 2023. Senior Vice President, Corporate Secretary and Associate General Counsel at McKesson from March 2018 to June 2021 and various other legal roles at McKesson from 2008 to 2018.
- Napoleon B. Rutledge Jr.
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Thomas L. Rodgers
Thomas L. Rodgers，自2020年6月起担任执行副总裁、首席战略和业务发展官。此前，2014-2020年担任McKesson Ventures高级副总裁兼董事总经理。
Thomas L. Rodgers,Executive Vice President, Chief Strategy and Business Development Officer since June 2020. Previously, Senior Vice President and Managing Director of McKesson Ventures from 2014 to 2020.- Thomas L. Rodgers，自2020年6月起担任执行副总裁、首席战略和业务发展官。此前，2014-2020年担任McKesson Ventures高级副总裁兼董事总经理。
- Thomas L. Rodgers,Executive Vice President, Chief Strategy and Business Development Officer since June 2020. Previously, Senior Vice President and Managing Director of McKesson Ventures from 2014 to 2020.